Mark J. O’Connor

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from <i>BRCA</i> Mutation Carriers

Peter C.C. Fong, David S. Boss, Timothy A. Yap et al. · New England Journal of Medicine · 2009 · 3.6K citations · Full text

Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition

Nuala McCabe, Nicholas C. Turner, Christopher J. Lord et al. · Cancer Research · 2006 · 1.3K citations

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

Sven Rottenberg, Janneke E. Jaspers, Ariena Kersbergen et al. · Proceedings of the National Academy of Sciences · 2008 · 943 citations · Full text

Breast Oncology, Pathology, Cancer Biology +17

Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action

Yves Pommier, Mark J. O’Connor, Johann S. de Bono · Science Translational Medicine · 2016 · 739 citations

4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2<i>H</i>-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1

Keith Menear, Claire Adcock, Robert Boulter et al. · Journal of Medicinal Chemistry · 2008 · 572 citations · Full text

Medicinal Chemistry, Polymerase Activation, Oral Bioavailability +15